Slideshows Images Quizzes

Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. See additional information.

Intrarosa

Last reviewed on RxList: 3/2/2018
Intrarosa Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Last reviewed on RxList 3/2/2018

Intrarosa (prasterone) vaginal insert is a steroid indicated for the treatment of moderate to severe difficult or painful sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy, due to menopause. Common side effects of Intrarosa include vaginal discharge, and abnormal Pap smear.

The dose of Intrarosa is one vaginal insert, once daily at bedtime. Intrarosa may interact with other drugs. Tell your doctor all medications and supplements you use. Intrarosa is only intended for use in postmenopausal women and is unlikely to be used during pregnancy or breastfeeding. Consult your doctor.

Our Intrarosa (prasterone) vaginal inserts Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

QUESTION

If menopause occurs in a woman younger than ___ years, it is considered to be premature. See Answer
Intrarosa Professional Information

SIDE EFFECTS

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In four (4) placebo-controlled, 12-week clinical trials [91% -White Caucasian non-Hispanic women, 7% -Black or African American women, and 2% -“Other” women, average age 58.8 years of age (range 40 to 80 years of age)], vaginal discharge is the most frequently reported treatment-emergent adverse reaction in the INTRAROSA treatment group with an incidence of ≥ 2 percent and greater than reported in the placebo treatment group. There were 38 cases in 665 participating postmenopausal women (5.71 percent) in the INTRAROSA treatment group compared to 17 cases in 464 participating postmenopausal women (3.66 percent) in the placebo treatment group.

In a 52-week non-comparative clinical trial [92% -White Caucasian non-Hispanic women, 6% Black or African American women, and 2% -“Other” women, average age 57.9 years of age (range 43 to 75 years of age)], vaginal discharge and abnormal Pap smear at 52 weeks were the most frequently reported treatment-emergent adverse reaction in women receiving INTRAROSA with an incidence of ≥ 2 percent. There were 74 cases of vaginal discharge (14.2 percent) and 11 cases of abnormal Pap smear (2.1 percent) in 521 participating postmenopausal women. The eleven (11) cases of abnormal Pap smear at 52 weeks include one (1) case of low-grade squamous intraepithelial lesion (LSIL), and ten (10) cases of atypical cells of undetermined significance (ASCUS).

Read the entire FDA prescribing information for Intrarosa (Prasterone)

SLIDESHOW

What Is Osteoporosis? Treatment, Symptoms, Medication See Slideshow
Related Resources for Intrarosa

© Intrarosa Patient Information is supplied by Cerner Multum, Inc. and Intrarosa Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors

CONTINUE SCROLLING FOR RELATED SLIDESHOW